Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
Puyuan XingQian ZhaoLi ZhangHanping WangDingzhi HuangPei HuYinghui SunYuan-Kai ShiPublished in: BMC medicine (2022)
ClinicalTrials.gov, NCT02695550.
Keyphrases
- open label
- endothelial cells
- clinical trial
- phase ii
- phase iii
- phase ii study
- computed tomography
- double blind
- study protocol
- image quality
- induced pluripotent stem cells
- contrast enhanced
- pluripotent stem cells
- cross sectional
- advanced non small cell lung cancer
- magnetic resonance imaging
- positron emission tomography
- randomized controlled trial
- tyrosine kinase